✦ LIBER ✦

A phase I trial of the pharmacokinetics, toxicity, and activity of KNI-272, an inhibitor of HIV-1 protease, in patients with AIDS or symptomatic HIV infection

✍ Scribed by Rachel W. Humphrey; Kathleen M. Wyvill; Bach-Yen Nguyen; Laura E. Shay; David R. Kohler; Seth M. Steinberg; Takamasa Ueno; Tominaga Fukasawa; Makoto Shintani; Hideya Hayashi; Hiroaki Mitsuya; Robert Yarchoan

Book ID: 114145192
Publisher: Elsevier Science
Year: 1999
Tongue: English
Weight: 143 KB
Volume: 41
Category: Article
ISSN: 0166-3542
DOI: 10.1016/s0166-3542(98)00058-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy of boceprevir, an NS3 protease

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

✍ Paul Y Kwo; Eric J Lawitz; Jonathan McCone; Eugene R Schiff; John M Vierling; Da 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 378 KB

Antiviral activity of the protease inhib

Antiviral activity of the protease inhibitor KNI-272 in vivo in the HIV-infected HuPBMC-SCID mouse model: Michael A. Ussery, Owen L. Wood, Dennis D. Broud, Matthew Bacho, Steven C. Kunder, Susan Papermaster, Yoshiaki Kiso1, and Paul L. Black. U.S.F.D.A., Rockville, MD, USA, and 1 Kyoto Pharmaceutical University, Kyoto, Japan

📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 130 KB